Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM, Tzianopoulos I, Liffers ST, Rosery VK, Guyot M, Ting S, Wiesweg M, Kasper S, Meister P, Herold T, Schmidt HH, Schumacher B, Albers D, Markus P, Treckmann J, Schuler M, Schildhaus HU, Siveke JT. Reissig TM, et al. Among authors: markus p. ESMO Open. 2023 Jun;8(3):101539. doi: 10.1016/j.esmoop.2023.101539. Epub 2023 May 4. ESMO Open. 2023. PMID: 37148593 Free PMC article.
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Maßmann M, Treckmann J, Markus P, Schumacher B, Albers D, Ting S, Mende B, Roehrle J, Virchow I, Rosery V, Laue K, Zaun G, Kostbade K, Pogorzelski M, Schmid KW, Baba H, Siveke JT, Paul A, Schildhaus HU, Schuler M, Wiesweg M, Kasper S. Maßmann M, et al. Among authors: markus p. J Cancer Res Clin Oncol. 2023 Jul;149(8):5085-5094. doi: 10.1007/s00432-022-04424-0. Epub 2022 Nov 5. J Cancer Res Clin Oncol. 2023. PMID: 36334155 Free PMC article.
Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting.
Zurloh M, Goetz M, Herold T, Treckmann J, Markus P, Schumacher B, Albers D, Rink A, Rosery V, Zaun G, Kostbade K, Pogorzelski M, Ting S, Schmidt H, Stiens R, Wiesweg M, Schuler M, Kasper S, Virchow I. Zurloh M, et al. Among authors: markus p. J Cancer Res Clin Oncol. 2023 Nov;149(14):12903-12912. doi: 10.1007/s00432-023-05141-y. Epub 2023 Jul 19. J Cancer Res Clin Oncol. 2023. PMID: 37466791 Free PMC article.
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.
Keyl J, Bucher A, Jungmann F, Hosch R, Ziller A, Armbruster R, Malkomes P, Reissig TM, Koitka S, Tzianopoulos I, Keyl P, Kostbade K, Albers D, Markus P, Treckmann J, Nassenstein K, Haubold J, Makowski M, Forsting M, Baba HA, Kasper S, Siveke JT, Nensa F, Schuler M, Kaissis G, Kleesiek J, Braren R. Keyl J, et al. Among authors: markus p. ESMO Open. 2024 Jan;9(1):102219. doi: 10.1016/j.esmoop.2023.102219. Epub 2024 Jan 8. ESMO Open. 2024. PMID: 38194881 Free PMC article.
Expert opinion on bleeding risk from invasive procedures in cirrhosis.
Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS, Villa E, Rautou PE; Bleeding in liver diseases investigators†; Bleeding in liver diseases investigators. Riescher-Tuczkiewicz A, et al. JHEP Rep. 2023 Dec 19;6(3):100986. doi: 10.1016/j.jhepr.2023.100986. eCollection 2024 Mar. JHEP Rep. 2023. PMID: 38384669 Free PMC article.
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J, Kasper S, Treckmann JW, Markus P, Schumacher B, Albers D, Wendling J, Ting S, Mende B, Maßmann M, Markus M, Virchow I, Rosery V, Laue K, Zaun G, Kostbade K, Pogorzelski M, Reissig TM, Liffers ST, Schmid K, Schildhaus HU, Schuler M, Siveke JT, Wiesweg M. Roehrle J, et al. Among authors: markus p. Oncol Res Treat. 2023;46(4):140-150. doi: 10.1159/000529452. Epub 2023 Jan 31. Oncol Res Treat. 2023. PMID: 36720216 Free article.
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Virchow I, Treckmann JW, Prasnikar N, Linden G, Markus P, Schumacher B, Albers D, Herold T, Ting S, Schmidt H, Radunz S, Wiesweg M, Siveke J, Schuler M, Kasper S. Virchow I, et al. Among authors: markus p. Oncol Res Treat. 2023;46(3):89-99. doi: 10.1159/000529012. Epub 2023 Jan 9. Oncol Res Treat. 2023. PMID: 36623497 Free article. Clinical Trial.
101 results